Clinical Daily Summary: What Happened on November 9, 2026

Foundayo improved sleep-apnea measures in Phase III

Lilly’s oral drug Foundayo met the primary endpoint in the Phase III ATTAIN-OSA study, lowering apnea-hypopnea index scores at 52 weeks in adults with overweight or obesity.1 Among participants not using positive airway pressure, the index fell by 21.1 events per hour with Foundayo and 5.5 with placebo.1 For participants using positive airway pressure, the reductions were 18.3 and 4.3 events per hour, respectively.1

Participants taking Foundayo lost an average of 28 pounds, and the study also found reductions in hypoxic burden, inflammation and systolic blood pressure.1 Gastrointestinal events were the most common adverse events. The overall safety profile was consistent with earlier Foundayo studies.1 Lilly said it plans to seek FDA approval for moderate-to-severe obstructive sleep apnea in adults with overweight or obesity by the end of 2026.1

Pelacarsen lowered lipoprotein(a) but did not cut cardiovascular events

Pelacarsen lowered blood levels of lipoprotein(a), a cardiovascular risk marker, but did not change heart attack or stroke rates in a Novartis study.2 The results were presented at the American Heart Association’s annual meeting.2

Faeth reports responses with endometrial-cancer combination

Faeth Therapeutics’ PIKTOR combination with paclitaxel produced confirmed tumor responses in 12 of 36 evaluable patients with advanced or recurrent endometrial cancer.3 The single-arm Phase II study enrolled patients whose cancers had PAM-pathway mutations and progressed after platinum chemotherapy and a checkpoint inhibitor.3

Median progression-free survival was 7.4 months, and 62% of patients had not progressed at six months.3 Seven percent stopped treatment because of adverse events, and the study reported no drug-related deaths.3 Faeth plans to advance the combination to Phase III but has not set a start date.3

Also worth knowing

• 

  Nkarta reported preliminary NKX019 results in small autoimmune-disease studies. Five of six myositis patients had moderate or major muscle-strength responses, and six of seven systemic-sclerosis patients reached at least a 25% response on a composite measure.5

• B

  Johnson & Johnson said 11 of 15 patients on its pasritamig-JNJ-9401 combination had PSA reductions of at least 50% in an early prostate-cancer study. No grade 3 or worse treatment-related events were reported in that group.6

• B

  UCB reported week-24 ACR50 responses of 54.9% with bimekizumab and 43.8% with risankizumab in psoriatic arthritis, describing the comparison as exploratory.7

• 

  Insilico Medicine reported partial responses in four of 22 evaluable mesothelioma patients treated with its experimental TEAD inhibitor ISM6331. The company said it plans a randomized Phase 2a study in 2027, subject to the data.8

• 

  In a Phase II stiff-person syndrome trial, 21 of 26 patients improved their walking ability by at least 20%. The study had no control group and a median follow-up of 6.5 months.9

• 

  Bristol Myers Squibb reported that 43 adolescents completed the first 28 weeks of the SCOUT-HCM trial and received Camzyos through week 56. No participant’s left ventricular ejection fraction fell below 50%.10

• N

  Resistance training three times a week reduced lean-tissue loss and improved strength during 40 weeks of tirzepatide treatment in a randomized trial of 120 adults with overweight or obesity.11

• 

  Sanofi stopped development of Nurix’s Phase I STAT6 degrader SAR448272. The companies’ broader collaboration remains in place.12

• 

  Immunocore estimated two-year survival at 70% among 17 evaluable patients receiving brenetafusp with Kimmtrak for metastatic uveal melanoma. The comparison with Kimmtrak alone came from an earlier trial, not a randomized control group.13

Also published

• Vir hepatitis D drug succeeds in first pivotal study BioPharma Dive
• Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study BioPharm International
• Therapeutic Immune Manipulation GEN
• Europe’s growing vector-borne disease threat: Are we keeping pace? pharmaphorum
• Effective Methods of Accurately Measuring Tumors Pharmaceutical Executive
• Translating Phase II success into Phase III readiness takes more than scale BioPharma Dive
• Novartis' pelacarsen fail raises questions for other drugs pharmaphorum
• OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC Clinical Trials Arena
• OCT New England 2026: Tackling the Patient Enrolment Crisis Clinical Trials Arena